文献速递乳腺癌头颈与中枢神经肿瘤

T-DM1治疗HER2阳性转移性乳腺癌伴脑转移:KAMILLA研究队列1探索性最终分析

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆.
PubMed 文献 · Ann Oncol · 2020-07-05

KAMILLA是一项IIIb期单臂研究,评估T-DM1(3.6 mg/kg 每3周)在经治HER2阳性晚期/转移性乳腺癌患者中的疗效与安全性。本次事后探索性分析聚焦398例基线脑转移患者,其中126例可测量脑转移灶的客观缓解率为21.4%,临床获益率为42.9%,中位无进展生存期5.5个月,中位总生存期18.9个月。T-DM1在该人群中显示活性且耐受性良好,神经系统不良事件在脑转移患者中更常见。

要点

  • T-DM1在HER2阳性转移性乳腺癌伴脑转移患者中显示颅内和全身抗肿瘤活性。
  • 可测量脑转移患者客观缓解率21.4%,临床获益率42.9%。
  • 脑转移患者中位PFS 5.5个月,中位OS 18.9个月,安全性总体可控。

核心结论

  • T-DM1在HER2阳性转移性乳腺癌伴基线脑转移患者中具有活性且耐受性良好,值得进一步探索。

研究设计与样本

  • KAMILLA为正在进行的IIIb期单臂研究,入组既往接受过HER2靶向治疗和化疗的HER2阳性局部晚期/转移性乳腺癌患者。
  • 患者接受T-DM1 3.6 mg/kg 每3周静脉输注,直至不可耐受毒性、撤回知情同意或疾病进展。
  • 本分析为事后探索性分析,评估基线脑转移患者的肿瘤缓解和临床结局,共2002例接受治疗患者中398例有基线脑转移。

主要发现

  • 126例可测量脑转移患者中,最佳总体缓解率为21.4%(95%CI 14.6-29.6),临床获益率为42.9%(95%CI 34.1-52.0)。
  • 脑转移灶最大径之和缩小≥30%者占42.9%(95%CI 34.1-52.0),其中既往未接受脑放疗的67例中该比例为49.3%(95%CI 36.9-61.8)。
  • 398例基线脑转移患者的中位无进展生存期为5.5个月(95%CI 5.3-5.6),中位总生存期为18.9个月(95%CI 17.1-21.3)。
  • 神经系统不良事件在基线脑转移患者中更常见(52.3% vs 43.7%),总体不良事件特征与无脑转移患者大致相似。

关键数值与推荐

  • 疗效评价采用RECIST v1.1标准,主要结局指标为最佳总体缓解率(完全缓解+部分缓解)和临床获益率(完全缓解+部分缓解+持续≥6个月的疾病稳定)。

临床怎么用

  • 对于既往接受过HER2靶向治疗和化疗的HER2阳性转移性乳腺癌伴脑转移患者,T-DM1可作为全身治疗选择之一。
  • 治疗期间需关注神经系统不良事件,尤其在基线脑转移患者中发生率更高。

局限性

  • 本分析为单臂研究的事后探索性分析,缺乏随机对照,结论需谨慎解读。
  • 脑转移亚组分析非预设主要终点,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with brain metastases (BM) from human epidermal growth factor receptor 2 (HER2)-positive breast cancer represent a difficult-to-treat population. Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patients in small clinical series. PATIENTS AND METHODS: KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer with prior HER2-targeted therapy and chemotherapy. Patients received T-DM1 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression. Tumor response and clinical outcomes in patients with baseline BM were evaluated in this post hoc, exploratory analysis. The main outcome measures were best overall response rate (complete response + partial response) and clinical benefit rate (complete response + partial response + stable disease lasting ≥6 months) by RECIST v1.1 criteria, progression-free survival, overall survival, and safety. RESULTS: Of 2002 treated patients, 398 had baseline BM. In 126 patients with measurable BM, the best overall response rate and clinical benefit rate were 21.4% [95% confidence interval (CI) 14.6-29.6] and 42.9% (95% CI 34.1-52.0), respectively. A reduction in the sum of the major diameters of BM ≥30% occurred in 42.9% (95% CI 34.1-52.0), including 49.3% (95% CI 36.9-61.8) of 67 patients without prior radiotherapy to BM. In the 398 patients with baseline BM, median progression-free survival and overall survival were 5.5 (95% CI 5.3-5.6) months and 18.9 (95% CI 17.1-21.3) months, respectively. The adverse event profile was broadly similar in patients with and without baseline BM, although nervous system adverse events were more common in patients with [208 (52.3%)] versus without [701 (43.7%)] baseline BM. CONCLUSION: This exploratory analysis of patients with HER2-positive metastatic breast cancer and BM enrolled in a prospective clinical trial shows that T-DM1 is active and well-tolerated in this population. T-DM1 should be explored further in this setting. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01702571.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆. Ann Oncol. 2020. PMID: 32634611. doi:10.1016/j.annonc.2020.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。